BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits ...
A groundbreaking genetic study in Kerala has identified a more aggressive Mpox variant, Clade Ib, linked to international ...
For individuals with compromised immune systems, chronic infections can be deadly. Thanks to a nearly $2 million grant, a professor in the Virginia-Maryland Regional College of Veterinary Medicine ...
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback